Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Steinberger

Interventional Cardiology Bismarck, ND Medical Doctor

NPI 1497241350 CMS profile 5609896

900 E Broadway Ave, Bismarck, ND 58501

Open in the dashboard

General payments

$8,516

112 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Steinberger of Bismarck, ND is reported in the CMS Open Payments database as having received $8,516 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,650 20
2024 General $2,238 31
2023 General $1,604 27
2022 General $1,292 20
2021 General $716 13
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Steinberger
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jared Steinberger were reported at $2,650. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jared Steinberger Interventional Cardiology median Middle half National median
2019 $17 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $716 $677 $233–$1,827 $132
2022 $1,292 $978 $333–$2,724 $149
2023 $1,604 $1,136 $382–$2,986 $160
2024 $2,238 $1,181 $395–$3,326 $164
2025 $2,650 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $2,107 18 payments
  2. Medtronic, Inc. $1,775 21 payments
  3. Abbott Laboratories $1,091 12 payments
  4. Amgen Inc. $723 6 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $643 20 payments
  6. Boston Scientific Corporation $438 5 payments
  7. Penumbra, Inc. $295 3 payments
  8. Janssen Pharmaceuticals, Inc $282 8 payments
  9. Abiomed $151 2 payments
  10. AngioDynamics, Inc. $145 1 payment
  11. Other $865 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,810 94 payments
  2. Travel and Lodging $2,386 14 payments
  3. Education $321 4 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $1,252 17 payments
  2. SAPIEN 3 Ultra RESILIA $1,223 15 payments
  3. Repatha $723 6 payments
  4. LifeVest $643 20 payments
  5. AMPLATZER AMULET $599 3 payments
  6. HawkOne $361 3 payments
  7. XARELTO $302 9 payments
  8. Penumbra System $277 2 payments
  9. DRAGONFLY OPSTAR $162 2 payments
  10. ONYX FRONTIER $161 1 payment
  11. Other $2,293 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

49

Median for Internal Medicine: 777

Drug cost

$7,051

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 15 $6,655
Clopidogrel Clopidogrel Bisulfate Brand 34 $396

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $126
$126 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $29
$29 — —
CLEVIPREX
  • CHIESI USA, INC. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record